Clinical trials: Advanced Disease
Carcinoma, Hepatocellular
Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Clinical trial of BAY43-9006 in patients with hepatocellular carcinoma.
- Trial name
- NCT00494299
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 75 sites in Japan, South Korea
- Volunteers
- 458 people
- Sponsor
- Bayer
Non-Small Cell Lung Cancer
TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy
The purpose of this study is to compare the safety and anti-tumor effect of rociletinib with erlotinib in patients whose tumors have specific EGFR mutations and who have not previously received any treatment for…
- Trial name
- EGFR (NCT02186301)
- Testing
- Rociletinib Mono-Therapy, Erlotinib Mono-Therapy
- Where
- 74 sites in United States, Germany and 5 more
- Volunteers
- 100 people
- Sponsor
- Clovis Oncology, Inc.
Ovarian Cancer
ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patient Clinical Response to Administered Chemotherapy in Patients
This is a prospective, non-randomized, observational, clinical development study. Pierian Biosciences is utilizing ChemoINTEL and ImmunoINTEL assay measurements in human tumour cells from patients with advanced stage epithelial…
- Trial name
- ChemoINtel (NCT06844136)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Pierian Biosciences
Advanced Cancer, Advanced Malignancies
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
- Trial name
- ARC-25 (NCT05891171)
- Testing
- AB598, Zimberelimab, Fluorouracil
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Arcus Biosciences, Inc.
Lung Cancer Metastatic, NSCLC Stage IV
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
This is an open-label, multi-center, single arm, phase II study to assess the anti-tumor activity and safety of bemcentinib in combination with pembrolizumab in up to 106 participants with previously treated, advanced…
- Conditions
- Lung Cancer Metastatic, NSCLC Stage IV, Adenocarcinoma of Lung
- Trial name
- NCT03184571
- Testing
- Pembrolizumab, Bemcentinib
- Where
- 13 sites in United States, Norway and 2 more
- Volunteers
- 99 people
- Sponsor
- BerGenBio ASA
GIST - Gastrointestinal Stromal Tumor
Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST
This is an open-label, single-arm, multicenter expanded access study to provide patients who have locally advanced unresectable or metastatic gastrointestinal stromal tumor (GIST) and have received treatment with at least 2 prior…
- Trial name
- NCT04148092
- Testing
- ripretinib
- Sponsor
- Deciphera Pharmaceuticals, LLC
Bladder Cancer
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
The purpose of this study is to determine whether Patients with Locally Advanced or Metastatic Bladder Cancer who receive Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus…
- Trial name
- NCT01126749
- Testing
- Gemcitabine, E7389, Cisplatin
- Where
- 42 sites in United States, Germany and 4 more
- Volunteers
- 92 people
- Sponsor
- Eisai Inc.
Lung Cancer, Non-Small Cell
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells [TC]/ Tumor proportion score [TPS] >= 50%), previously untreated, unresectable…
- Trial name
- NCT05565378
- Testing
- Pembrolizumab, Dostarlimab, Belrestotug
- Where
- 99 sites in United States, Argentina and 20 more
- Volunteers
- 351 people
- Sponsor
- GlaxoSmithKline
Triple-Negative Breast Cancer
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of magrolimab in combination with nab-paclitaxel or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in…
- Trial name
- ELEVATE TNBC (NCT04958785)
- Testing
- Magrolimab, Nab-Paclitaxel, Paclitaxel
- Where
- 45 sites in United States, Australia and 4 more
- Volunteers
- 92 people
- Sponsor
- Gilead Sciences
Geographic Atrophy
A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
This study is open to adults with geographic atrophy, an advanced form of age-related macular degeneration. People can join the study if they are at least 50 years old.
- Trial name
- NCT06006585
- Testing
- BI 771716
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Age-related Macular Degeneration
Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration
The purpose of this study is to evaluate the safety, tolerability, and serum pharmacokinetics of CLG561 in subjects with advanced age-related macular degeneration (AMD).
- Trial name
- NCT01835015
- Testing
- CLG561
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Triple Negative Breast Neoplasms
A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
This study is designed to evaluate the preliminary anti-tumor activity and tolerability of PF-03084014 when administered as a single agent in the treatment of patients with advanced triple receptor-negative breast cancer (mTNBC)…
- Trial name
- NCT02299635
- Testing
- PF-03084014
- Where
- 37 sites in United States, Hungary and 4 more
- Volunteers
- 19 people
- Sponsor
- Pfizer
Oral Mucositis
Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the duration or length of severe oral mucositis in patients with head and neck cancers.
- Trial name
- PREVLAR (NCT03515538)
- Testing
- RRx-001, Cisplatin for injection, Radiation Therapy
- Where
- 12 sites in United States
- Volunteers
- 53 people
- Sponsor
- EpicentRx, Inc.
HER2-positive Solid Tumors, HER2-positive Breast Cancer
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies
- Conditions
- HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer
- Trial name
- NCT04278144
- Testing
- BDC-1001, Nivolumab
- Where
- 21 sites in United States, France and 2 more
- Volunteers
- 175 people
- Sponsor
- Bolt Biotherapeutics, Inc.
Carcinoma, Non-Small-Cell Lung
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
The purpose of this study is to confirm the tolerability of recommended Phase 2 dose (RP2D) of Lazertinib (Phase 1), to determine the tolerability and identify the recommended Phase 2 combination dose of Lazertinib when combined…
- Trial name
- Chrysalis-2 (NCT04077463)
- Testing
- Lazertinib, Amivantamab, Carboplatin
- Where
- 78 sites in United States, China and 8 more
- Volunteers
- 701 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Prostate Cancer
A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer
The purpose of the protocol is to assess the rate of castration resistance, disease progression and overall survival over a 3-year period post-androgen deprivation therapy (ADT) induction in a study cohort of patients with…
- Trial name
- TRIPTOCARE LT (NCT01383863)
- Where
- 35 sites in Denmark, France and 5 more
- Volunteers
- 180 people
- Sponsor
- Ipsen
Stage III Ovarian Carcinoma, Stage IV Ovarian Carcinoma
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas
This is a double-blind study in which approximately 99 study patients will be randomized in a 2:1 ratio to receive either AVOVA-1 or MC.
- Conditions
- Stage III Ovarian Carcinoma, Stage IV Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT02033616
- Testing
- AVOVA-1, MC
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Aivita Biomedical, Inc.
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- OVATION 2 (NCT03393884)
- Testing
- IMNN-001, Carboplatin, Paclitaxel
- Where
- 21 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Imunon
Metastatic Pancreatic Cancer, Colorectal Cancer
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
The purpose of this study is to confirm the safety and tolerability of TAK-931 in a cohort of Western participants with metastatic solid tumors and to evaluate the anti-tumor activity of TAK-931 in participants with metastatic…
- Conditions
- Metastatic Pancreatic Cancer, Colorectal Cancer, Esophageal Neoplasms, Carcinoma, Non-small-cell Lung
- Trial name
- NCT03261947
- Testing
- TAK-931
- Where
- 10 sites in United States, Japan
- Volunteers
- 101 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Solid Tumors, Hematological Malignancies
A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors
This is a prospective, randomized, open-label, Phase I, crossover study to assess the effect of food on the bioavailability of AXL1717 including patients with advanced malignant tumors
- Trial name
- NCT01725555
- Testing
- Fasted treatment: AXL1717, Fed treatment: AXL1717
- Where
- Sweden
- Volunteers
- 13 people
- Sponsor
- Axelar AB
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.